FEASIBILITY AND EFFICACY OF COMBINED TREATMENT WITH ELTROMBOPAG AND DEFERASIROX IN PATIENTS AFFECTED BY APLASTIC ANEMIA

EHA Library, Daniela Cilloni, 216392

A RARE CAUSE OF ANEMIA: GHOSAL TYPE HEMATO-DIAPHYSEAL DYSPLASIA

EHA Library, Begum Koc, 216393

CLINICOHEMATOLOGICAL AND CYTOGENETIC PROFILE OF APLASTIC ANEMIA IN PAKISTAN

EHA Library, Nida Anwar, 216394

HUMAN MONOCLONAL IGG DERIVED FROM PATIENTS WITH MULTIPLE MYELOMA ARE ABLE TO PENETRATE LIVING NEOPLASTIC CELLS AND EXHIBIT INTRACELLULAR BIOLOGICAL FUNCTIONS

EHA Library, Evangelos Terpos, 216395

PDCD1, PDL1 AND CTLA4 POLYMORPHISMS ASSOCIATED WITH THE SUSCEPTIBILITY TO AND CLINICAL FEATURES OF MULTIPLE MYELOMA.

EHA Library, Tetsuhiro Kasamatsu, 216396

CIRCULATING EXOSOMAL LONG NON-CODING RNA PRINS – FIRST FINDINGS IN MONOCLONAL GAMMOPATHIES

EHA Library, Dávid Vrábel, 216397

PDGFR-Β AND CXCR4 IN MULTIPLE MYELOMA DISEASE STAGES: PRELIMINARY RESULTS

EHA Library, Leonor Correia, 216398

THE NOVEL TRANSLOCATION OF T(1;21) IN MULTIPLE MYELOMA WITH COMPLEX KARYOTYPE

EHA Library, Mufide OKAY, 216399

ANALYZING BONE AND EXTRAMEDULLARY PLASMACYTOMA SUBSTRATES IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Maiia Soloveva, 216400

INTRODUCTION OF A EUROPEAN QUALITY ASSESSMENT SCHEME FOR GENETIC TESTING IN MYELOMA: PROGRESS AND UPDATE.

EHA Library, Polly Talley, 216401

RAMAN SPECTROSCOPY IS ABLE TO DISCRIMINATE BETWEEN CD138-/CD138+ PLASMA CELLS OF MULTIPLE MYELOMA PATIENTS.

EHA Library, Alessandro Allegra, 216402

NOVEL THERAPEUTICS FOR MULTIPLE MYELOMA TESTED IN A 3D BONE MARROW MODEL

EHA Library, Maaike Braham, 216403

CIRCULATING TUMOR DNA ANALYSIS OF KRAS, NRAS AND BRAF MUTATIONS USING MASS SPECTROMETRY IN MULTIPLE MYELOMA PATIENTS

EHA Library, Liang-Tsai Hsiao, 216405

THE MOLECULAR SIGNATURES OF HIGH RISK MULTIPLE MYELOMA IN THAI POPULATION

EHA Library, Parin Kamseng, 216406

TARGETING SIGLEC-7: A NOVEL IMMUNOTHERAPEUTIC APPROACH TO POTENTIATE THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA

EHA Library, John Daly, 216407

STUDY OF MULTIPLE MYELOMA CHROMOSOMAL ABNORMALITIES BY MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION: CORRELATIONS WITH FLUORESCENCE IN SITU HYBRIDIZATION

EHA Library, Flavia Carbone, 216408

ALTERED MICRORNA EXPRESSION PROFILE IN THE PERIPHERAL LYMPHOMONOCYTES OF MULTIPLE MYELOMA PATIENTS WITH BISPHOSPHONATE-INDUCED OSTEONECROSIS OF THE JAW.

EHA Library, Vanessa Innao, 216409

A ROLE OF LIGHT AS POTENTIAL BIOMARKER FOR PROGRESSION OF SMOLDERING TO SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Rita Rizzi, 216410

DIFFERENTIAL MIRNOME EXPRESSION PROFILE IN NON TUMOR LYMPHOMONOCYTES OF THE PERIPHERAL COMPARTMENT OF MGUS SUBJECTS

EHA Library, Oriana Francesca Bianco, 216411

DETECTION OF MYD88 L265P MUTATION BY DIGITAL PCR IN PERIPHERAL BLOOD SAMPLES FROM IGM MONOCLONAL GAMMOPATHY PATIENTS

EHA Library, Nieves Garcia-Gisbert, 216412

IMPACT OF THE EXPRESSION OF LRP GENE ON THE SENSITIVITY OF TUMOR PLASMA CELLS TO BORTEZOMIB IN VIVO AND IN VITRO

EHA Library, Yulia Chernykh, 216413

EFFECT OF AUTOLOGOUS STEM CELLS TRANSPLANTATION OF PATIENTS WITH MULTIPLE MYELOMA ON THE CALORIMETRIC MARKERS OF THE SERUM PROTEOME. CORRELATION WITH THE IMMUNOLOGICAL MARKERS

EHA Library, Lidia Gartcheva, 216414

PODOCYTURIA IN MULTIPLE MYELOMA PATIENTS HAS A TENDENCY TO INCREASE WİTH TREATMENT

EHA Library, Emel Gurkan, 216415

RELATIONSHIP OF MOLECULAR PECULIARITIES WITH CYTOGENETIC ABERRATIONS IN MULTIPLE MYELOMA

EHA Library, Elena Nazarova, 216416

ACTIVIN A: A NOVEL URINARY BIOMARKER REFLECTING EARLY RENAL IMPAIRMENT IN MULTIPLE MYELOMA

EHA Library, Hirono Iriuchishima, 216417

BONE MARROW MESENCHYMAL STROMAL CELLS FROM HEALTHY DONORS SECRETE ANTI-ANGIOGENIC EXTRACELLULAR VESICLES AS WELL AS SOLUBLE FACTORS HAVING GROWTH INHIBITORY EFFECT IN MULTIPLE MYELOMA

EHA Library, Tomohiro UMEZU, 216418

MOGROL REPRESENTS A NOVEL ANTI-MYELOMA AGENT VIA ERK AND NF-ΚB INHIBITION

EHA Library, Shidai Mu, 216419

MYELOMA CELL DEATH INDUCED BY ZEBULARINE LEADS TO CMYC DOWNREGULATION AND IS DECREASED BY CYTIDINE DEAMINASE OVEREXPRESSION.

EHA Library, Patryk Krzeminski, 216420

FEATURES OF STROMAL BONE MARROW MICROENVIRONMENT IN PATIENTS WITH MULTIPLE MYELOMA WITH INEFFECTIVE TRANSPLANTATION OF PERIPHERAL HEMATOPOIETIC STEM CELLS

EHA Library, Natalya Semenova, 216422

HIGH-RISK YOUNG MULTIPLE MYELOMA PATIENTS TREATED UP-FRONT WITH LENALIDOMIDE: IMPACT OF KIR 3DL1-EDU AND KIR HAPLOTYPES ON CLINICAL OUTCOME

EHA Library, Fabrizio Puglisi, 216423

ASSOCIATION OF HLA-SPECIFICITIES OF CLASSES I, II WITH IMMUNOCHEMICAL VARIANTS OF MULTIPLE MYELOMA

EHA Library, Elena Poponina, 216424

RECONSIDERING JAK2 IN AN INTER-TUMOUR HETEROGENEITY OF MULTIPLE MYELOMA

EHA Library, Teerapong Siriboonpiputtana, 216425

MOLECULAR CYTOGENETIC ANALYSIS IN MULTIPLE MYELOMA/PLASMA CELL LEUKEMIA PATIENTS WITH CIRCULATING PLASMA CELLS

EHA Library, Jana Balcarkova, 216426

THE INVOLVEMENT OF MESANGIOGENIC PROGENITOR CELLS IN MULTIPLE MYELOMA PATHOGENESIS

EHA Library, Claudia Pia Schifone, 216427

MYELOID AND LYMPHOID DENDRITIC CELLS IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE - POSSIBLE LINK WITH DISEASE PROGRESSION

EHA Library, Ewelina Grywalska, 216428

QUANTIFICATION AND CHARACTERIZATION OF BONE MARROW MESENCHYMAL STROMAL CELLS IN MONOCLONAL GAMMOPATHIES

EHA Library, João Barradas, 216429

ASSOCIATION OF CLINICAL RESPONSE WITH SURVIVAL AND QUALITY OF LIFE (QOL) AFTER CARFILZOMIB AND DEXAMETHASONE (KD56) TREATMENT IN THE PHASE 3 ENDEAVOR TRIAL

EHA Library, David Siegel, 216431

MINIMAL RESIDUAL DISEASE NEGATIVITY AFTER MOLECULARLY TARGETED VENETOCLAX THERAPY OF SECONDARY PLASMA CELL LEUKEMIA WITH TRANSLOCATION T(11;14)

EHA Library, Gabor Mikala, 216432

ASSESSMENT OF PNEUMOCOCCAL VACCINATION RESPONSE IN MULTIPLE MYELOMA

EHA Library, Marc Ellis, 216433

THE DETERMINATION OF FACTORS AFFECTING ON THE PROGRESSION-FREE SURVIVAL OF MULTIPLE MYELOMA PATIENTS

EHA Library, Andrei Garifullin, 216434

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 216435

EARLY RELAPSE AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION IS A MAJOR PREDICTIVE FACTOR OF LOWER OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS

EHA Library, Adriana Roque, 216436

PROGNOSTIC SIGNIFICANCE OF THE CHROMOSOME 1 ABNORMALITIES IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Jelena Bila, 216437

GOOD OUTCOMES USING ACTIVE TREATMENT WITH NOVEL AGENTS IN ELDERLY MYELOMA PATIENTS

EHA Library, Nadishani Ediriwickrama, 216438

SURVIVAL OF RELAPSED MYELOMA PATIENTS WITH A SECOND AUTOGRAFT: LOCAL EXPERIENCE

EHA Library, Craig Hendry, 216439

PHASE 2 STUDY FOR CARFILZOMIB PLUS ELOTUZUMAB PLUS DEXAMETHASONE FOR MYELOMA PATIENTS RELAPSED AFTER 1-3 PRIOR TREATMENT LINES

EHA Library, Raija Silvennoinen, 216440

ORAL CYCLOPHOSPHAMIDE’S ADDITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT

EHA Library, Laura Cesini, 216441

DETECTION OF ASYMPTOMATIC FEMORAL HEAD AVASCULAR NECROSIS ON ROUTINE WHOLE BODY MRI IN PATIENTS WITH MULTIPLE MYELOMA PROVIDES OPPORTUNITIES FOR JOINT PRESERVATION.

EHA Library, Priya Sriskandarajah, 216442

ELIGIBILITY CRITERIA FOR CLINICAL TRIALS AND COMORBIDITY AS PREDICTORS OF CHEMOTHERAPY DOSE ADJUSTMENT IN PATIENTS WITH MULTIPLE MYELOMA.

EHA Library, Ernesto Pérez Persona, 216443

MONTELUKAST AND GEMFIBROZIL WHEN ADDED TO BORTEZOMIB BASED THERAPY INDUCES RAPID RESPONSE IN PATIENTS WITH REFRACTORY AND HIGH RISK DISEASE.

EHA Library, Stephen O'Mara, 216444

EARLY PARAPROTEIN REDUCTION AND RESPONSE TO FIRST-LINE TREATMENT IN MULTIPLE MYELOMA

EHA Library, Moritz Binder, 216445

PROGNOSTIC SIGNIFICANCE OF HEAVY/LIGHT CHAIN RATIO IN INTACT IMMUNOGLOBULIN MULTIPLE MYELOMA PATIENTS-PRELIMINARY RESULTS

EHA Library, Ioannis Kakkas, 216446

EFFICACY, SAFETY AND TOLERABILITY OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) REGIMEN IN RR/MM

EHA Library, Valeria Calafiore, 216447

HIGH IMPLEMENTATION ADHERENCE TO LENALIDOMIDE IN MULTIPLE MYELOMA

EHA Library, IRINA AMITAI, 216448

RETROSPECTIVE AUDIT OF BISPHOSPHONATE USE IN MULTIPLE MYELOMA PATIENTS IN TWO DISTRICT GENERAL HOSPITALS AND FRACTURE CONSENSUS

EHA Library, Zahbia Saleem, 216449

BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE

EHA Library, Claudio Cerchione, 216450

POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 216451

BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 216452

A COMPARATIVE ANALYSIS OF FREE LIGHT CHAIN CONCENTRATIONS IN SERUM AND CEREBROSPINAL FLUID FOR PATIENTS WITH MULTIPLE MYELOMA COMPLICATED BY MYELORADICULOPATHY

EHA Library, Елена Трифонова, 216453

SALVAGE THERAPY WITH POMALIDOMIDE-BASED REGIMEN IN RELAPSED/REFRACTORY MYELOMA. EFFICACY, AND SAFETY RESULTS.

EHA Library, Maialen Sirvent Auzmendi, 216454

SPLENIC INVOLVEMENT IN AL AMYLOIDOSIS: A CAUSE FOR PANCYTOSIS

EHA Library, Andreea Jercan, 216455

MULTIPLE MYELOMA AND INFECTIONS IN THE “NOVEL AGENTS ERA”: A REAL-LIFE RETROSPECTIVE UNICENTRIC EXPERIENCE.

EHA Library, Maria Stefania Infante, 216456

EFFECTIVENESS OF BENDAMUSTINE IN RELAPSED OR REFRACTORY AL AMYLOIDOSIS

EHA Library, Nathalie Forgeard, 216457

IMPACT OF IMPROVEMENT IN RENAL FUNCTION AND WAITING TIME BEFORE INDUCTION THERAPY ON SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Nikolett Wohner, 216458

FREQUENCY AND CAUSES OF NOT RECEIVING SUCCESSIVE LINES OF TREATMENT IN REFRACTORY MULTIPLE MYELOMA: A CROSS-SECTIONAL STUDY.

EHA Library, Alicia Senín, 216459

MONOCLONAL GAMMOPATHY AND TRANSTHYRETIN AMYLOIDOSIS.

EHA Library, Ana Alarcon, 216460

RISK FACTORS FOR EARLY MORTALITY IN MULTIPLE MYELOMA WITH DIFFERENT SURVIVAL TIME CUT-OFF POINTS: REAL-LIFE DATA

EHA Library, Seda Balaban, 216462

MONTELUKAST COMBINED WITH THE LIPID LOWERING DRUG GEMFIBROZIL REVERSES RESISTANCE TO COMBINATION CHEMOTHERAPY IN PATIENTS WITH MULTIPLE MYELOMA. RESULTS OF PROSPECTIVE PHASE 1 / 2 CLINICAL TRIAL.

EHA Library, Stephen O'Mara, 216463

NORWEGIAN REAL-LIFE EXPERIENCE OF PREAPPROVAL CARFILZOMIB THROUGH COMPASSIONATE USE NAMED PATIENT PROGRAM (NPP) FOR RELAPSING/REFRACTORY MYELOMA (RRMM)

EHA Library, Ina Haarstad, 216464

DOES ASYMPTOMATIC D-DIMER ELEVATION PREDICT THROMBOSIS IN PATIENTS ON IMMUNOMODULATORY DRUGS IN MULTIPLE MYELOMA: REAL-LIFE DATA

EHA Library, Seda Balaban, 216465

EFFICACY OF NEW DRUGS PRIOR TO SINGLE OR TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. A SINGLE CENTER EXPERIENCE

EHA Library, Sara Grammatico, 216466

DEGREE OF VULNERABILITY IN PATIENTS WITH MULTIPLE MYELOMA: A COMPARATIVE STUDY BETWEEN THE APPLICATION OF CLINICAL JUDGMENT AND THE SCALE OF ASSESSMENT (GA SCALE)

EHA Library, Eugenia Abella, 216468

BLEEDING AND THROMBOTIC COMPLICATIONS IN PLASMA CELL DISORDERS IN THE "NOVEL AGENTS ERA": RISK FACTORS, OUTCOME ,PROGRESSION AND STRATEGIES OF PREVENTION.A REAL-LIFE MONOCENTRIC RETROSPECTIVE ANALYSIS

EHA Library, Lorenza Torti, 216469

OUTCOME OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH PCCD (POMALIDOMIDE - CYCLOPHOSPHAMIDE-CLARITHROMYCIN - LOW DOSE DEXAMETHASONE) IN THE REAL-LIFE SETTING

EHA Library, Rafael Rios-Tamayo, 216470

REAL WORLD DATA OF AGE RELATED CYTOGENETIC ABNORMALITY DISTRIBUTION IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS: SINGLE CENTRE EXPERIENCE FROM THE UNITED KINGDOM

EHA Library, Jennifer Tam, 216471

OUTCOME OF PATIENTS WITH MULTIPLE MYELOMA AND RENAL FAILURE IN ERA OF NOVEL AGENTS- EXPERIENCE OF A TERTIARY CARE CENTRE FROM NORTHERN INDIA.

EHA Library, Nitin Gupta, 216472

EFFICACY OF RETREATMENT WITH IMMUNOMODULATORY DRUGS AND PROTEASOME INHIBITORS FOLLOWING DARATUMUMAB MONOTHERAPY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS

EHA Library, Rimke Oostvogels, 216474

CLINICAL FEATURES AND OUTCOMES OF SOLITARY PLASMACYTOMAS: SINGLE-CENTER EXPERIENCE FROM TURKEY

EHA Library, Yusuf Ulusoy, 216475

RESPONSE TO INDUCTION THERAPY IN MULTIPLE MYELOMA PATIENTS; A SINGLE CENTRE EXPERIENCE.

EHA Library, Munira Borhany, 216476

SERVICE DELIVERY OF APPROVED DARATUMUMAB TREATMENT FOR RELAPSED MYELOMA; CHALLENGES OF NORMAL IMMUNOGLOBULIN AND UNAFFECTED FREE LIGHT CHAIN SUPPRESSION, ESPECIALLY WHEN ASCT IS INCLUDED.

EHA Library, Raymond Powles, 216477

LIGHT-CHAIN DEPOSITION DISEASE: DIAGNOSIS AND TREATMENT CHALLENGES. A SINGLE CENTER EXPERIENCE

EHA Library, SORINA BADELITA, 216478

BULKY EXTRAMEDULLARY SOFT-TISSUE PLASMACYTOMAS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER EXPERIENCE FROM NORTH INDIA

EHA Library, Uttam Kumar Nath, 216479

MYC REARRANGEMENT IN COHORT OF NEWLY DIAGNOSED SLOVENIAN MM PATIENTS

EHA Library, Helena Podgornik, 216480

MAINTENANCE TREATMENT WITH THALIDOMIDE AFTER FRONTLINE BORTEZOMIB-BASED REGIMENS IN TRANSPLANTATION INELIGIBLE PATIENTS WITH MYELOMA MULTIPLE (MM). EXPERIENCE OF REAL LIFE.

EHA Library, Dunia De Miguel Llorente, 216481

CT AND MRI MAY RESULT IN OVERDIAGNOSIS OF SKELETAL DISEASE IN MULTIPLE MYELOMA

EHA Library, Anders Erik Astrup Dahm, 216482

RENAL SALVAGE WITH BORTEZOMIB / CYCLOPHOSPHAMIDE / DEXAMETHASONE INDUCTION THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL INSUFFICIENCY: A SINGLE-CENTER STUDY FROM NORTH INDIA

EHA Library, Uttam Kumar Nath, 216483

ANALYTICAL CRITICALITIES ASSOCIATED TO DIFFERENT METHODS FOR SERUM FREE LIGHT CHAIN DETECTION: IMPACT ON THE INTERNATIONAL MYELOMA WORKING GROUP (IMWG) CRITERIA DEFINING SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Katja Weisel, 216484

POMALIDOMIDE PLUS DEXAMETHASONE (PD) IN THE TREATMENT OF ASIAN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA (RRMM) WHO ARE PREVIOUSLY REFRACTORY TO LENALIDOMIDE–A TRIAL BY THE ASIAN MYELOMA NETWORK (AMN)

EHA Library, Wj Chng, 216485

INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA IN A LARGE NATIONWIDE HEALTH PLAN IN ISRAEL

EHA Library, Clara Weil, 216486

YOUNG ADULTS WITH MULTIPLE MYELOMA – UNVEILING A DIFFERENT SPECTRUM IN A RESOURCE CONSTRAINED SETTING

EHA Library, Sumeet Mirgh, 216487

AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA AND RENAL FAILURE

EHA Library, Lauren Foster, 216488

EFFECT OF COMPOUND KUSHEN INJECTION ON IMMUNE FUNCTION FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING CHEMOTHERAPY

EHA Library, Honglei Tu, 216489

EFFICACY AND SAFETY OF TREATMENT WITH BORTEZOMIB,CYCLOPHOSPHAMIDE,DEXAMETHASONE （VCD) VERSUS BORTEZOMIB,DEXAMETHASONE(VD) REGIMENS IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA(NDMM)

EHA Library, Ma Liangming, 216490

BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION THERAPY IS COMPARABLE TO BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA: A SINGLE CENTRE EXPERIENCE

EHA Library, Firas Al-Kaisi, 216491

PROGNOSTIC SIGNIFICANCE OF THE REVISED INTERNATIONAL STAGING SYSTEM IN TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Jelena Bila, 216492

KRD TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL LIFE EXPERIENCE

EHA Library, Gregorio Barilà, 216493

THE AUTOPHAGY INHIBITOR HYDROXYCHLOROQUINE ADDED TO THALIDOMIDE BASED THERAPY FOR MULTIPLE MYELOMA DEEPENS RESPONSE AND PROLONGS REMISSION IN PATIENTS PREVIOUSLY TREATED WITH THALIDOMIDE.

EHA Library, Stephen O'Mara, 216494

PROGNOSTIC ROLE OF NEUTROPHIL-LYMPHOCYTE RATIO IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Alexander Luchinin, 216495

FACTORS ASSOCIATED WITH RENAL FAILURE AND RENAL FUNCTION RECOVERY IN MULTIPLE MYELOMA

EHA Library, Aysun SENTURK YIKILMAZ, 216496

AUTOLOGOUS TRANSPLANTATION WITH REDUCED PRE-TRANSPLANT CONDITIONING IN PATIENTS WITH MULTIPLE MYELOMA AT A HIGHER AGE - TOXICITY VERSUS EFFICACY.

EHA Library, Alexandra JUNGOVA, 216497